Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for global professionals · Sunday, September 22, 2019 · 497,082,317 Articles · 3+ Million Readers

7-digit investment in future technology genetic testing

Potential of genetic testing increasingly attracts big investors

Our vision is to make a genetic test as affordable and easy to obtain as a conventional blood test.”
— Dr. Albert Kriegner

VIENNA, AUSTRIA, August 12, 2019 / -- 7-digit investment in future technology genetic testing
Medical diagnostics is undergoing a groundbreaking digital revolution and a visionary Austrian company is leading the way in personalized medicine. In concrete terms, Platomics is developing a digital platform for the analysis of genetic data. This enables the genetic blueprint to be deciphered and better understood.

The technical background
The sequencing of the human genome for personalized diagnosis generates huge amounts of data. In recent years, new sequencing technologies have made it relatively easy and fast to read these data. For the interpretation of the data, however, highly complex analysis procedures are necessary. Genetic tests are already standard in special application areas such as prenatal tests or cancer diagnosis. However, genetic testing is still too cost-intensive in everyday medical practice.

Why genetic testing?
If correctly interpreted, genetic tests can help to better understand the development of diseases and thus significantly improve diagnosis and therapy. The effects and side effects of drugs are also significantly influenced by the genetic blueprint. Dr. Albert Kriegner, CEO of Platomics, says that the broad application of genetic tests is therefore imminent: "We are undergoing medical, technological and regulatory upheaval. Groundbreaking findings will fundamentally change medical diagnostics in the coming years. Platomics is at the forefront of shaping this paradigm shift towards personalized medicine. Our vision is to make a genetic test as affordable and easy to obtain as a conventional blood test." Platomics is a spin-off of the renowned Austrian Institute of Technology, where Kriegner headed the Department of Bioinformatics.

The product in practice
Diagnostic laboratories of physicians and hospitals already use the platform for standardized and validated analysis of their genetic data. An exchange with genetic centres enables a practical implementation of the platform. Customers particularly appreciate the extraordinarily high precision, sensitivity and user-friendliness combined with maximum data security. In the end, the patient and the healthcare system benefit from tailor-made diagnostics, therapy and medication.

Next Steps
The investment will expand Platomics' activities in the core areas of regulatory compliance, big data analysis, artificial intelligence, data security, software development and bioinformatics.

Martin Lorenz
Platomics GmbH
+43 660 2220395
email us here

Powered by EIN Presswire

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release